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Background 
Diabetes and its related complications create significant burden to the health system in 
Australia. Between 2000/01 and 2008/09, total health expenditure on diabetes increased by 
86% to $1,507 million or 2.3% of total health expenditure in 2008/09.1 This increase was 
26% more than the increase in total health expenditure.1 
Indigenous Australians experience a disproportionally high burden of diabetes, responsible 
for 12% of the large gap in disability-adjusted life years between Indigenous and non-
Indigenous people.2 Indigenous Australians also have higher rates of hospitalisation for 
diabetes (3.4-5.0 times higher) and higher mortality rates (7.0 times higher) than non-
Indigenous Australians.3 Indigenous Australians are also more likely to develop type 2 
diabetes at an earlier age.4 It is well-established that persistent high blood glucose levels 
result in organ damage, resulting in renal complications, circulatory and ophthalmic 
conditions. Indigenous Australians experience exceptionally high rates of complications, 
including 11.2 times the rate of hospitalisation for renal failure4 and less effective care 
partnerships with their clinicians.5 It is therefore important to develop clinical programs to 
support the better management of diabetes and its complications for Indigenous people. 
It was hypothesised that Indigenous Health Workers (IHWs), who are close to the 
community linguistically and culturally, could play an important role in improving the quality 
of primary health care for Indigenous Australians and contribute to better health outcomes. 
A trial of a recall system in remote Indigenous communities managed by local IHWs 
supported by a diabetes outreach service reported improved diabetes care and lower 
hospitalisations.6,7 A 2006 study on the delivery of diabetes care in remote Indigenous 
communities found that employing more IHWs was independently associated with improved 
diabetes care, but not better HbA1c control.8 Further testing of the role of IHW was 
indicated. 
The Getting Better At Chronic Care Project (GBACC) was a cluster-randomised-control trial 
(cluster-RCT) designed to improve the care of persons with poorly controlled diabetes living 
in 12 rural and remote Indigenous communities in north Queensland. Participants in the six 
intervention communities received in addition to standard primary care, intensive chronic 
condition management for 18 months delivered by IHWs, who had a Certificate level 3 or 4 
in Aboriginal and Torres Strait Islander Primary Health Care, which covers a broad spectrum 
of primary health care work. These IHWs received additional training in diabetes 
management and intensive support from the clinical support team. The model was family-
centred and based on community out-reach. Control (usual care, UC) communities received 
care as usual from a centre-based primary care team (nurses, GPs, IHWs etc.), but 
involving less intensive IHW support. Service configurations vary somewhat across the 
communities.9 Primary clincial results, which found a modest improvement in glycemic 
control in the intervention sites compared to controls, have been published elsewhere.10 A 
process evaluation concluded that there was significant implementation failure during the 
18-month intervention phase, largely as a consequence of unforeseen service disruptions 
due to major restructure of services provided by Queensland Health in five of the six 
intervention sites. While this was also an issue in three of six control sites, the IHW model 
required an effective working relationship between the IHW and other members of the 
clinical team which was undermined by the service disruptions.11  
This paper reports on two economic evaluations of the GBACC project. The first evaluation 
completed a cost-consequence analysis, in which the costs of implementing the model are 
compared with differential changes in a range of health outcome measures of study 
participants in the intervention and usual care groups. 
The second economic evaluation looked at hospitalisations related to diabetes, especially 
those which had been shown in previous reports to be excessive among remote Indigenous 
adults, mostly acute preventable diabetes-related infections and complications.  
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THE INTERVENTION  
Each site allocated to the intervention arm recruited an Indigenous Health Worker resident 
in the community (selected by the health service) to work as part of the primary care team, 
and allocated a caseload of between 9 and 26 clients. The health workers with low 
caseloads worked part-time. All health workers at the commencement of the study received 
an intensive 3-week training in clinical aspects of diabetes and other chronic condition care, 
including how to support patients in self-management skills, advice on medications, routine 
foot care, nutrition, smoking cessation, follow up referrals to other providers, and scheduled 
tests. The roles of the health workers included helping patients make and keep 
appointments, understand their medications and nutrition and the effects of smoking and 
where appropriate, work with the family to help support the patient in self-management. 
Home visits and out-of-clinic care were a feature of the trial, however visits were conducted 
according to the patients’ preferences. 
The curriculum included specific training and practice in: 
 Rationale for the chronic care model and evidence-based management and 
treatment goals in diabetes, hypertension, COPD, renal disease and CHD 
 Hands-on case management, supported by the clinical team 
 Working in a primary care team, with clear roles and responsibilities of team 
members 
 Engaging with families and using local resources to support effective client self-
management. 
During the 18-month intervention period, the health workers attended two workshops where 
they underwent refresher training, including in Good Clinical Practice and reflective practice. 
During these sessions, they reported on their patients’ progress and shared approaches to 
problem solving with the clinical support team and peers. In addition, the CHWs kept an 
activity log and prepared monthly activity reports. 
IMPLEMENTATION  
All planned training (initial three weeks clinical training, 6-monthly in-service training), weekly 
teleconferences and scheduled outreach visits by the clinical support team were performed. 
All trial community health workers were employed by the existing health service in the 
participating intervention sites, as part of the primary care team. During the early phase of 
the trial, the Queensland Government health services underwent a radical restructure, 
including the loss of many clinical and service support positions. These changes affected 
eight of the 12 trial sites, including four in the intervention group. The immediate impact of 
these changes was a shortfall in clinic staff in many sites, especially the smaller sites, and 
extensive delays in replacing key staff when they left. This often meant that the health 
workers in the study were called upon to undertake other clinical work apart from their 
assigned clients in the trial. Other effects of the restructure were manifest in a shortfall in 
visiting specialist services, including diabetes-related staff, which potentially impacted on the 
rate of referrals and uptake of these services during the trial implementation phase. 
MEASURES 
The primary outcome measure, glycaemic control (HbA1c) was measured by Queensland 
Medical Laboratories using standard high-pressure liquid chromatography methods. 
Secondary outcomes included changes from baseline in blood pressure, height, weight, 
serum fasting lipids (cholesterol fractions and triglycerides) and urinary albumin creatinine 
ratio (UACR) and were abstracted from clinic files and electronic records. Taking insulin was 
defined as having any of long-acting, medium- or short-acting insulin. Albuminuria was 
defined as urinary ACR≥3.4 (albumin to creatinine ratio or urine microalbumin). 
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The Test of Functional Health Literacy for Adults (TOFHLA) was administered at study 
enrolment to all participants to gauge the patients’ general understanding of health 
messages and procedures. In general, TOFHLA was scored highly in both groups, and it 
was concluded that they would not have major difficulty working with the diabetes care 
team. 
Quality of Life was estimated using the Assessment of Quality of Life (AQoL) instrument, a 
multi-attribute utility instrument developed using Australian importance weights. Socio-
demographic data was by self-report, including years of formal education, household 
income, employment, food insecurity (“Do you frequently not have enough money to buy 
food?”), current smoking and medication adherence.  
Process measures included guideline-recommended clinical checks, including General 
Practitioner Management Plans (GPMP) and specialist referrals (13), and were abstracted 
from primary care records at follow-up for the previous 18 months. For patients with clinical 
indications, appropriate medication use was recorded, including oral hypoglycaemic agents, 
insulin, statins, ACEi (angiotensin-converting-enzyme inhibitor), or angiotensin receptor 
blockers (ARB) or blood pressure control drugs, and vaccination. 
The intervention was implemented between March 2011 and September 2012. The 
participant flow diagram is summarized in Figure 1. 
CLINICAL RESULTS OF THE TRIAL  
At baseline, there were no significant differences between allocation groups in age (mean 
age 47.9 years), sex ratio (62% women), employment status, years of schooling, median 
household income, self-reported food insecurity, household size, median AQoL score on the 
mental health scale, smoking prevalence, HbA1c (10.7%) and mean BMI (32.5). The 
intervention group scored lower on the health literacy test. 
At follow-up, 45.2% (95% CI, 34.5-56.0%) of patients in the intervention group had a current 
GP Management Plan (GPMP) for diabetes compared to 35.5% (26.3-44.7) in the waitlist 
group (OR 1.23, 95%CI, 0.72-2.22). There was no association between having a GPMP at 
follow-up and HbA1c change from baseline. This may be due to the fact that many GPMPs 
were done within six months of the follow-up data collection point, so the chance for the 
GPMP to have an immediate impact would be small. Further follow up may show a stronger 
relationship between having a GPMP and improved clinical indicators. 
Other clinical care processes, including routine checks and specialist referrals, medications 
and self-reported smoking and medication adherence were completed at baseline and 
follow-up. Intervention group patients were significantly more likely to have seen a dietician 
and dentist and slightly more likely to have seen a diabetes educator, be taking insulin and 
having influenza vaccination. Waitlist group patients showed greater self-reported 
adherence to prescribed medicines and were slightly more likely to have had an eye 
examination and be self-monitoring for glucose. Despite very high rates of dyslipidaemia 
there was generally very low uptake of lipid lowering treatment in both groups, and the high 
smoking rates were unchanged. Appropriate management of albuminuria was high in both 
groups. 
There was a significant decrease in HbA1c of 1% from baseline in the intervention group, 
from 10.8% (95mmol/mol) to 9.8% (84mmol/mol) compared to the waitlist group, which 
showed a less marked decrease of 0.2% from 10.6% (92mmol/mol) to 10.3% (89mmol/mol), 
(p=0.018) and based on the GEE model. More people in the intervention group achieved at 
least a 0.5% interval reduction in HbA1c (67.5%, 57.3-77.7) than in the waitlist group 
(48.6%, 38.9-58.2). There were small improvements in both groups for total cholesterol, LDL 
cholesterol, cholesterol:HDL ratio, with slightly better results in the intervention group. Blood 
pressure and weight decreased in the waitlist group and increased slightly in the intervention 
group. None of these effects were statistically significant at the 5% level. 
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The impact of Health Service Model (community controlled (CC) versus not CC) on the 
likelihood of a participant having a GPMP was explored independently of whether the trial 
site was in the intervention or the control group allocation. The percentage of GPMPs 
completed in sites with a community-controlled service was 71.0% compared to 23.5% 
among the non-CC sites (OR = 3.0, 95% confidence interval, 1.2-7.5 after adjustment for 
clustering) (Table 5). However there were no differences in clinical measures between CC 
and non-CC sites at follow-up. 
In summary, the trial suffered from implementation failure in many of the intervention sites, 
and overall achieved a modest improvement in glycaemic control in the HW-led model 
compared to usual care. 
 
Figure 1: CONSORT Flow Diagram: Getting Better at Chronic Care Cluster RCT 
  
Assessed for eligibility (n=12 
clusters and 327 patients) 
Excluded (n=114 patients) 
 
   Declined to participate (n=114  ) 
   Other reasons (n=0  ) 
Analysed for primary outcome (n=83, 83%) 
 
Lost to follow-up or discontinued (n=16) 
 (12 moved away and 4 died)  
Allocated to intervention (n=6 clusters and 100 
patients) 
 Received allocated intervention (n=100 ) 
 Did not receive allocated intervention (n=0) 
Lost to follow-up or discontinued (n=6) 
(3 moved away, 2 died and 1 withdrew) 
Allocated to waitlist control (n=6 clusters and 
113 patients) 
 Received allocated intervention (n=113  ) 
 Did not receive allocated intervention (n=0) 
Analysed for primary outcome (n=108, 96%) 
 
 
A L L O C A T I O N  
A N A L Y S I S  
F O L L O W - U P  
Cluster Randomized (n=12 clusters and 213 participants) 
E N R O L L M E N T  
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Methods: First economic evaluation 
The first evaluation conducted an economic analysis alongside a cluster-RCT. Details of the 
trial design, participants, sample size, outcomes and ethics approvals are described 
elsewhere.9 Briefly, study participants were Aboriginal and Torres Strait Islander (TSI) adults 
with poorly controlled T2DM (HbA1c≥ 8.5%) and at least one other chronic condition. The 
primary clinical goal was a differential mean reduction in HbA1c of 1.0% over the trial (IHW 
compared to UC). 
MEASUREMENT OF COSTS  
We calculated the per-person cost to implement the intervention, drawing on project costing 
records. The primary task was to allocate costs between i) service delivery/support and ii) 
management and evaluation activities related to the task of running a trial. Costs were 
separately analysed for the central team and the IHWs. 
Costs for the central team 
Costs for the central team included, 
 Expenses relating to the trial manager and the clinical support team who were 
responsible for IHW training (developing training materials, training delivery) 
 Enhancing the quality of clinical practice through mentoring, advocacy and reflective 
practice with IHWs, convening IHW meetings, clinical reference group meetings and 
team meetings 
 Evaluation as an embedded component (data collection, data entry, conference 
presentations, workshops), and 
 Coordination of project activities including chief investigator and management group 
meetings. 
Costs were extracted from project financial reports between 01/01/2011 (commencement of 
the project with trial set up) and 30/09/2013 (trial endpoint). The percentage of time the 
manager and the clinical support team allocated to the trial versus the evaluation were 
determined by the trial manager (BS), after detailed discussion with LS and HN about the 
type of activities to be classed as intervention or non-intervention, (evaluation and trial 
coordination activities). 
IHW Salaries (including wage on-costs) 
Salaries in the six intervention communities were identified from project records. The 
percentage of IHW time allocated to intervention participants and non-intervention activities 
was determined from detailed time logs kept by the IHWs. The IHW cost was the sum of the 
product of total wage costs and percentage of time allocated to the project by each IHW. 
MEASUREMENT OF OUTCOMES  
The primary outcome for the clinical trial was the differential change in HbA1c comparing 
IHW and UC after 18 months of trial delivery. HbA1c measurements were extracted from 
participants’ clinical files. The baseline value was the HbA1c measure closest to the 
participants’ recruitment date and the endpoint was the one closest to the trial endpoint. For 
the economic evaluation, we also explored the distribution of HbA1c, given the limitations of 
using the mean to describe a distribution. Thus we also estimated HbA1c outcomes in terms 
of shift in number with ‘moderate’, ‘poor’ and ‘extremely poor’ control (as described below), 
given a relationship between level of control and health consequences. 
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Secondary study outcomes included differential change in quality of life score, disease 
progression and rates of hospitalisation. Quality of life was measured by the Assessment of 
Quality of Life 4D (AQoL-4D), which has four dimensions (independent living, relationships, 
mental health and senses), each with three items and four levels. The AQoL was developed 
in Australia and the algorithm to estimate the utility score was derived from an Australian 
population.12 Its use in an Australian Indigenous population has not been validated. 
Disease progression was assessed by allocating a disease stage to each participant using a 
diabetes severity staging instrument developed by Gibson et al.13 
The instrument classifies diabetes into four stages, 
1) T2DM with no evidence of microvascular or macrovascular risk factors 
2) T2DM with screen-detected microvascular comorbidities and/or risk factors for 
macrovascular disease 
3) T2DM with moderate microvascular or macrovascular complications, and 
4) Late stage T2DM microvascular or macrovascular complications. 
The instrument uses clinical markers and hospitalisation data to allocate each study 
participant to a disease stage. For baseline disease stage, we drew on baseline clinical data 
and hospitalisations between 01/07/2010 and 01/03/2012 and for endpoint disease stage 
clinical data and hospitalisations between 01/03/2012 and 05/09/2013. The disease stages 
are defined to be monotonic. Once allocated to a stage, there is no possibility of reverting to 
a less severe disease stage. 
Hospitalisation data were derived from the Queensland Hospital Admitted Patients Data 
Collection which covers all patient separations (discharges, deaths and transfers) from all 
recognised public and licensed private hospitals in Queensland.14 Data were obtained for all 
inpatient episodes for study participants discharged between 01/07/2010 and 05/09/2013. 
This covered all inpatient discharges during a 19-20 month pre-intervention period and 18 
months concurrent with the intervention. Hospitalisations were categorised into four groups 
based on ICD 10 codes, 
 All hospitalisations 
 Hospitalisations with principal or other diagnoses related to T2DM (“E11” code in the 
principal or other diagnoses) 
 Ambulatory Care Sensitive (ACS) hospitalisations related to chronic disease (used 
by the AIHW to estimate ACS hospitalisations for Aboriginal and Torres Strait 
Islander people15, and 
 The top three ACS condition categories (T2DM principal diagnosis, Cardiovascular 
diseases (CVD) and Infections).16 Hospital costs were taken from the same records, 
and were length of stay adjusted DRG costs.17 
STATISTICAL ANALYSES  
The statistical analysis was conducted on an intention-to-treat basis and in accordance with 
current guidelines for clinical and economic analysis alongside a cluster-RCT to measure 
differential costs and consequences.18 We adopted methods that take into account the 
clustering (within community) and correlation of cost and outcome data. Among available 
methods for economic analysis of cluster-RCT19, we applied the linear multilevel models 
(MLMs). MLMs acknowledge clustering by including additional random terms, which 
represent the differences in the cluster mean (costs and outcomes) from the overall means 
in each intervention group. MLMs are efficient, provide good coverage for confidence 
interval of estimates and are applicable to RCTs with less than 10 clusters in each trial 
arm.18 Analyses were undertaken using Stata 12.0. 
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We used a Markov model to describe disease progression for the IHW and UC group. The 
probability of staying in the current state or moving to a more severe disease stage between 
baseline and endpoint is estimated and presented in a transition matrix. This is a simple way 
of presenting rate of disease progression and testing for any effect of the intervention.20  
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Results: First economic evaluation 
There were 100 participants enrolled in the IHW group and 113 in the UC group. Of these, 
87 in the IHW and 106 in the UC group met the study inclusion criteria of HbA1c equal or 
greater than 8.5%. Table 1 shows some demographic characteristics and risk factors at 
baseline for participants who met the inclusion criteria. There were no statistically significant 
differences between the two groups at baseline in terms of age, BMI, smoking or alcohol 
use. 
Table 1. Baseline characteristics of study participants 
 Usual care (N=106) IHW (N=87) 
p-value  
n 
% or mean 
(SD) n 
% or mean 
(SD) 
Age in years (mean) 106 47.6 (8.7) 87 47.5 (10.6) 0.958* 
BMI (mean) 43 32.6 (6.2) 44 31.2 (  6.3) 0.522* 
Female (%) 70 66.0 53 60.1 0.533^ 
Daily smoker (%) 38 37.3 34 40.5 0.654^ 
Current drinker (%) 39 40.7 36 45.6 0.511^ 
Obesity – BMI ≥ 30 (%) 28 65.1 23 52.3 0.280^ 
Notes: * p-values of t-test for equal means in IHW and usual care groups taking into account 
clustering 
 ^ p-values of chi-square test of equal proportions in IHW and usual care groups taking into 
account clustering 
 
COSTS OF THE INTERVENTION  
All expenditure from the commencement of the project to the trial endpoint is summarised in 
Table 2. Total expenditure was $1,991,904, of which $1,006,027 was attributed to 
intervention delivery. The remaining costs were allocated to research and other non-
intervention activities. Total salaries (including wage on-costs) for the IHWs were $690,989. 
Three IHWs were employed full-time and three part-time. After adjusting for IHW 
involvement in other activities (between 6% and 56% of their time); the cost for the IHWs 
attributed to the intervention was $522,421. To this is added the attributed costs of the trial 
manager and clinical support team of $483,606. 
With 100 persons receiving the intervention, the average per-person cost of delivering the 
intervention was $10,060 ($1,006,027 ÷ 100). This represents the best estimate of the costs 
of rolling out the model incorporating the same elements as the GBACC. Based on an 18-
month service delivery period, this is equivalent to $6,707 per-person per year. 
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Table 2. Total cost estimates – Getting Better at Chronic Care Project 
 
Total Trial 
Expenditure  
Time and Cost 
allocated to GBACC 
intervention 
 $ %^ $ 
Central (control) team     
Clinical Support Team 626,091 57 357,353 
Management 234,624 10 23,462 
Operation 440,200 23 102,791 
Sub-Total 1,300,915 37 483,606 
Indigenous Health Workers    
Community A  151,551 78 118,210 
Community B 151,551 64 96,993 
Community C 75,775 44 33,341 
Community D 78,028 89 69,445 
Community E 156,056 84 131,087 
Community F 78,028 94 73,346 
Sub-Total 690,989 76 522,421 
Grand total 1,991,904 51 1,006,027 
Source: project financial reports 
Notes:   ^  The allocation of the project team time between research and service delivery was 
determined by the program manager, reflecting her knowledge of tasks and roles. 
Allocation of Indigenous Health Worker (IHW) time to GBACC was based on time records. 
 
EFFECTIVENESS OF THE INTERVENTION  
Results of the incremental effectiveness analyses are reported in Table 3. This includes 
change in mean HbA1c between the IHW and the UC groups between baseline and 
endpoint and the differential change between the two groups adjusting for clustering. The 
mean reduction in HbA1c of -0.93% in the IHW group was non-significantly (p-value=0.17) 
greater than that in the UC group of -0.49%. Both groups experienced a slight fall in quality 
of life with no significant difference (p-value=0.62). This is slightly different to the result 
reported in McDermott et al.10 due to the exclusion of participants who failed to meet the 
study inclusion criteria in the current analysis. 
In terms of distribution of HbA1c, there was a statistically significantly reduction in the 
proportion of participants with extremely poor control HbA1c (≥ 11.5) in the IHW group, 
(42.0% to 23.5%), compared to a slight increase in the UC group (35.1% to 37.1%) (p-
value=0.002) (Figure 2). If the change observed in the IHW group had been achieved by the 
UC group, the expected number of persons with HbA1c ≥11.5% would have been 17 less 
(17 = 97 × 37.1% − (97 × 35.1%) × [
42.0%−23.5%
42.0%
]) 
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Table 3. Summary of the incremental effectiveness analyses (change between baseline and 
trial end) 
 
Usual care (n = 106) 
Indigenous health worker-
supported (n = 87) 
Difference of 
differences† 
(95% CI) P Baseline Endpoint Change* Baseline Endpoint Change* 
HbA1c level (SD), 
mmol/mol 
94.7 
(19.0) 
89.3 
(24.1) 
–5.4 (n = 
97) 
99.0 
(17.4) 
88.8 (25.7) –10.1 (n 
= 81) 
–4.7 (–11.6 to 
2.1) 
0.174 
AQoL-4D, mean 
utility score (SD) 
0.80 
(0.18) 
0.79 
(0.21) 
–0.01 0.75 
(0.18) 
0.72 (0.28) –0.03 –0.02 (–0.08 to 
0.05) 
0.623 
Rate of hospitalisation (per person per year; total number of admissions in parentheses) 
All causes, 
excluding dialysis‡ 
1.02 
(172) 
1.24 
(176) 
0.22 0.98 
(135) 
1.07 (124) 0.09 –0.13 (–0.68 to 
0.41) 
0.633 
Type 2 diabetes, 
any diagnosis§ 
0.53 (88) 0.92 
(128) 
0.39 0.47 (64) 0.78 (88) 0.31 –0.08 (–0.20 to 
0.03) 
0.150 
Ambulatory care 
sensitive 
        
All¶ 0.33 (58) 0.44 (60) 0.11 0.31 (45) 0.30 (36) –0.01 –0.11 (–1.04 to 
0.81) 
0.811 
Type 2 diabetes as 
principal 
diagnosis** 
0.15 (26) 0.18 (23) 0.03 0.17 (23) 0.11 (13) –0.06 –0.09 (–0.18 to 
0.00) 
0.063 
Cardiovascular 
disease†† 
0.01 (1) 0.08 (12) 0.07 0.02 (3) 0.04 (5) 0.02 –0.05 (–0.13 to 
0.02) 
0.149 
Infections‡‡ 0.13 (21) 0.14 (20) 0.02 0.10 (14) 0.09 (11) –0.01 –0.03 (–0.10 to 
0.04) 
0.362 
Mean hospitalisation cost (per person per year) 
All causes $5438 $7421 $1982 $8010 $9866 $1856 –126 (–5024 to 
4771) 
0.960 
Type 2 diabetes, 
any diagnosis§ 
$4248 $6582 $2335 $4921 $8595 $3674 1340 (–2724 to 
5404) 
0.518 
Ambulatory care 
sensitive 
        
All¶ $1665 $2132 $467 $2967 $2677 –$290 –757 (–2130 to 
616) 
0.280 
Type 2 diabetes as 
principal 
diagnosis** 
$907 $1245 $338 $1553 $1245 –$308 –646 (–1348 to 
56) 
0.071 
Cardiovascular 
disease†† 
$23 $163 $140 $239 $383 $144 4 (–749 to 757) 0.992 
Infections‡‡ $623 $609 –$14 $1040 $451 –$589 –574 (–1490 to 
342) 
0.219 
AQoL-4D = Assessment of Quality of Life 4D score. * Only participants for whom baseline HbA1c 
levels were measured after 1 January 2009 and endpoint levels after 1 March 2012 were included. † 
Estimates for incremental difference in outcomes between usual care and IHW groups using linear 
multi-level models adjusted for within-community clustering. ‡ Two people in the IHW group had 
dialysis after the intervention commenced (starting July 2012 and March 2013); their dialysis records 
were excluded. § International Classification of Diseases, revision 10 (ICD-10) code in principal or any 
other diagnoses starting with E11. ¶ All potentially preventable hospitalisations (ICD code in principal 
diagnosis: D501, D508, D509, E101–E108, E110–E118, E130–E138, E140–E148, E40–E43, E550, 
E643, E86, G40, G41, H66, H67, I10, I119, I110, I20, I240, I248, I249, I50, J02, J03, J06, J20, J312, 
J41–J44, J45, J46, J47, J81, K02–K06, K08, K098, K099, K12, K13, K250–K252, K254, K255, K256, 
K260–K262, K264–K266, K270–K272, K274–K276, K35–K37, K522, K528, K529, L03, L04, L08, L88, 
L980, L983, N10–N12, N136, N390, N70, N73, N74, O15, R02 or R56).16 ** ICD-10 code in principal 
diagnosis starts with E11. †† ICD-10 code in principal diagnosis: I10, I110, I119, I20, I240, I248, I249, 
J81 or I50. ‡‡ ICD-10 code in principal diagnosis: H66, H67, J02, J03, J06, J312, L03, L04, L08, L980, 
L88, L983, N10–N12, N136, N390, N70, N73, N74, or R02. 
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Figure 2. Distribution of HbA1c categories at baseline and endpoint 
 
 
 
Notes: Only participants with baseline HbA1c measured after 01/01/2009 and endpoint 
HbA1c measured after 01/03/2012 were included (nUC = 97, nIHW=81). 
 
There was no significant difference in the change in any of the hospitalisation categories. 
Rates of all-cause hospitalisations (excluding dialysis) and T2DM related-any diagnosis 
increased in both groups; with a small observed difference in favour of the IHW not 
significant. Ambulatory care sensitive hospitalisations increased slightly in the UC group with 
rates unchanged in the IHW group. The difference was not statistically significant (p-
value=0.81). Where diabetes was the primary diagnosis there was a differential net 
reduction in the admission rate of 0.09/person-year, the only category to approach statistical 
significance (p-value=0.06). But the size of effect is small at eight fewer hospitalisations per 
year across the 87 IHW participants (relative to total admissions of 18 per year). Still, the 
data suggest a possible small improvement in morbidity. 
Annualised hospital costs are also reported in Table 3. Across most categories, a small 
relative reduction is observed in the IHW group, which only approaches significance for 
T2DM as primary diagnosis. If this observed reduction in hospitalisations for T2DM were a 
true result, this would indicate a cost saving of $646 per person per year, a small offset 
against the intervention cost of $6,700 per person year. 
The probability of transitioning into later disease stages (e.g. from stage 2 to stage 3/4, or 
stage 3 to stage 4) between the baseline and follow-up disease stage allocation (a mean 
period of 28.5 months) was considerable for both the IHW and UC groups. The observed 
differences between the IHW and UC group were not statistically significant (p-value=0.73). 
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COST-EFFECTIVENESS OF THE INTERVENTION  
At an additional cost of just over $6,700 per participant per year with no significant 
improvement in mean HbA1c, rate of disease progression or QoL; but a significant reduction 
in hospitalisation for T2DM primary diagnosis yielding an estimated saving of $646, which if 
true gives a net intervention cost of just over $6,000 per person per year or $9,000 for the 
18 month trial. Taking the other significant finding of a reduction in the number of persons 
with very poorly controlled diabetes this gives a cost of $42,880 per person whose HbA1c 
moves out of the critically high level of ≥11.5% (
$9,000×81
17
). 
  
P a g e  | 16 
Methods: Second economic evaluation 
The main outcome measures for this evaluation were hospitalizations by principle diagnosis 
(ICD-10), length of stay, hospitalizations for acute infections and acute severe diabetes-
related events. Eleven main categories of hospitalizations were generated according to the 
likelihood of them being affected by the CHW model of care (Table 4). 
 
Table 4. Categories of hospitalisation events for trial participants, 01/07/2010 to 05/09/2013 
Group Group name ICD-10 codes from Principal Diagnosis 
field only 
1 DM as principal disease E1173, E1165, E1164, E1169, E1064, E1122, 
E1172, E1065, E1073, E1135, E1161, E119, 
E872, I2511 (14) 
2 Heart disease, stroke, and 
hypertension 
R074, I214, I500, I200, R073, I209, J81, I210, 
I64, G459, I208, I211, I10, I212, I238, I259, 
I269, I440, I489, I501, I629, I634, I639, I802, 
I841, R001, T828  (27) 
3 CKD, other renal disease N185, Z490, E877, N059, N131, N139, N183, 
N359 (8) 
4 Infections L0311, N390, J189, M8697, A419, J22, N12, 
J440, M8667, L024, R509, T8141, A241, B86, 
J180, K358, L0310, N10, N61, N764, A099, 
H663, K613, L022, L023, L0302, M0096, 
M8698, A083, A090, A244, A4151, B349, 
H664, H700, J100, J853, K750, L028, L033, 
L088, L732, L989, M0094, M8668, M8688, 
N730, N750, R508, , T827, T835 (51)  
5 Injury, arthritis, myalgia L97, F100, S6230, T874, F101, M546, S099, 
T813, G728, H160, H720, H728, M1316, M542, 
M545, M6096, M6286,  M6289, M6787, M751, 
M7912, S0602, S298, S499, S6188, S6252, 
S6300, S798, S826, S921, S930, T383, T612, 
T793, J90, S010, S0269 (37)  
6 Cancer, neoplasm C349, C519, C509, C518, C64, D125, D231, 
D236, D251, D259, D27, D350, D410, E042, 
N63 (15) 
7 Elective surgery or admission, not 
diabetes related  
H269, R104, Z509, G560, H110, K430, N132, 
R02, R101, R33, Z488, Z492, E875, H001, 
H359, H409, H904, K102, K130, M203, M204, 
N823, S0005, T172, T810, Z433, Z466, Z508, 
Z598, Z7511 (30) 
8 Anaemia, GI symptoms, pancreatitis, 
gall bladder and liver disease 
K2970, K859, D509, K2920, K529, D649, I881, 
K590, K729, K8050, K810, K811,K852, K922, 
D508, E611, E780, K219, K2990, K37, K429, 
K439, K460, K621, K701, K8010, K830, K851 
(28) 
9 Mental health, neurological problems R410, R55, F3290, F430, R42, R51, R568, 
F3220, F432, G518, I951 (11) 
10 Obstetric & gynaecological conditions O2412, O82, N832, N871, N920, N946, O039, 
O11, O13, O998, Z301 (11) 
11 COPD/asthma/other respiratory (non-
infections) 
J459, J449, R042 (3) 
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STATISTICAL ANALYSIS  
Hospital admissions 
This analysis used a baseline “Before” period of 1 July 2010 – 1 March 2012 (20 months) 
and an intervention “After” follow up period of 2 March 2012 – 1 September 2013. 
For this analysis, renal dialysis admissions were excluded as were admissions with ICD 
code Z763 (Healthy person accompanying sick person). For analysis of the prevalence of 
admissions (i.e., admitted one or more times), each participant had a single record in the 
file. For incident admissions, each participant had either a single record showing no 
admission, or a separate record for each admission, hence each subject could have none, 
or multiple admissions. In the intervention period, the number of admissions per person 
ranged from 0 – 24. In the follow up period, the number of admissions ranged from 0 – 26. 
Time on trial was estimated as 20 months for the intervention period, less days in hospital, 
and 18 months in the follow up period less days in hospital. Where the person died (all 
deaths were in the follow up period), deaths were assumed to have occurred mid-way 
through the period and the time on trial was halved. Although there were 6 deaths of 
participants, two occurred after the end of the trial. 
Time on trial was summed for all participants including those not admitted to hospital. 
Although a number of participants were lost to follow up, we were still able to obtain their 
hospital records as long as any admissions occurred in Queensland. It is likely that this was 
the case in the majority of those lost to follow up. Analysis was by intention to treat for all 
participants enrolled. 
Prevalence data (admitted at least once) were analysed using a logistic regression model, 
adjusting for clustering by individual and community and using time on trial as the exposure 
variable. The model included as independent variables: group, period, and a group-period 
interaction term, the latter being the formal test of an intervention effect. Incidence data were 
analysed similarly but using log binomial generalized linear models. 
Length of stay (LOS) was analysed for all those admitted to hospital with exclusions as 
above. Although length of stay is highly skewed, means and SEMs are provided for 
descriptive statistics to allow for economic modelling. LOS was modelled using a gamma 
identity generalized linear model, adjusting for clustering by individual and community. The 
model included as independent variables: group, period, and a group-period interaction 
term, the latter being the formal test of an intervention effect. 
Economic analysis 
The time frame for the economic evaluation was the duration of the intervention period, with 
analysis conducted from a health provider perspective. The number of diabetes acute 
complications or acute severe infections hospitalisations prevented was chosen as the focal 
outcome because this is an area of health system performance that could be improved by 
the trial. Therefore, costs incurred during hospitalisation were not taken into account, rather 
only the costs of implementing the intervention were considered. 
The number of patients needed to be treated (NNT) to prevent one diabetes acute 
complications or acute severe infections hospitalisation was calculated based upon the 
Actual Control Rate (ACR) of diabetes acute complications or acute severe infections 
hospitalisations for patients who underwent usual care; and the adjusted-relative risk (RR) of 
diabetes acute complications or acute severe infections hospitalisation for the intervention 
group compared to the control group. The formula used to calculate NNT was: 
NNT = (1/(100 x ACR x (1 – RR))) 
The incremental cost-effectiveness ratio (ICER) was estimated from the difference between 
the total cost of the intervention multiplied by the number of patients that needed to be 
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treated (NNT) to prevent one hospitalization for diabetes acute complication or acute severe 
infection, where ACR = 81 per 113 = 0.72 and RR = 0.59 
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Results: Second economic evaluation 
Hospital separations were captured for the 20 months prior and the 18 months following 
commencement of the trial, a total of 370 separations (excluding dialysis) in the control 
group and 292 separations in the intervention group. 
Overall 50.7% of participants were admitted to hospital at least once in the before period, 
compared to 43.1% in the after period.  The intervention group had a 42% increased odds of 
being admitted one or more times to hospital after allowing for baseline admission 
prevalence, however, this was not statistically significant (p=0.254). 
Compared to baseline, hospital separations at 18 months for all causes per person per year 
increased in both groups, but with a slightly smaller rise in the intervention group. The 
intervention group had a 3% increased rate of being admitted for any condition after allowing 
for baseline admission incidence, however, this was not statistically significant (p=0.696) 
(Table 5). 
For Diabetes as the Principal Diagnosis, at baseline, rates were similar in both groups and 
remained unchanged in the control group. There was a significant reduction in rates per 
person year in the intervention group compared to controls (OR 0.20 95% CI: 0.08-0.51). 
For groups 1 and 4 combined, which represent both diabetes acute complications and acute 
severe infections, intervention groups were 41% less likely to be admitted (RR 0.59 (95% 
confidence interval 0.38-0.91), p=0.09) (Table 6). For the four conditions which are directly 
related to diabetes (groups 1-4 inclusive) the intervention groups were 35% less likely to be 
admitted (RR 0.64 (0.49-0.85), p=0.002) (Table 6). 
For those hospitalisations which were not directly related to diabetes care (groups 5-11) the 
intervention group had a 226% increased rate of being admitted after allowing for baseline 
admission incidence, and this was statistically significant (p=0.001) (Table 6). The biggest 
differences accounting for this observed increase in the intervention group were for elective 
surgery, cancer, gastro-intestinal complaints and mental health problems.  
Cost comparison between intervention and control groups to prevent unnecessary 
hospitalizations. Based on the above reported RR of 0.59 (95% CI: 0.38 – 0.91) for being 
admitted to hospital for diabetes acute complications and acute severe infections for the 
intervention group relative to the control group, the number needed to treat (NNT) was 3 
patients treated to prevent 1 hospital admission. The overall intervention cost was 
AUS$10,060 more per patient than routine care. The incremental healthcare cost to prevent 
one diabetes acute complication and acute severe infection complication using this 
intervention was AUS$30,180 (Table 7).  
 
Table 5. Hospitalization episodes by condition group, intervention and control groups 
(N=617) 
 Control group 
n=351 
Treatment 
group n=266 
Total n=617 
Diagnosis groups Before After Before After Before After 
1. Diabetes 28 24 29 13 57 37 
2. CVD 9 20 19 27 28 47 
3. Renal 4 19 0 7 4 26 
4. Infections 50 57 45 30 95 87 
5. Injury, arthritis 17 17 13 11 30 28 
6. Cancer 8 0 2 7 10 7 
7. Elective surgery 30 15 9 15 39 30 
8. GI conditions 16 14 8 14 24 28 
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9. Mental, neurological 4 2 7 7 11 9 
10. Obs & Gynecology 7 4 1 1 8 5 
11. Respiratory 4 2 1 0 5 2 
 
 
Table 6. Incident hospital admissions by condition groupings 
 Control group Intervention group 
 Before After Before After 
Episodes (All) 177 174 134 132 
Person days 137990 128717 111715 95825 
Incidence Rate (All) / 100,000 
person days (95% CI) 
128.27 
(110.07 – 
148.62) 
135.18 
(115.84 – 
156.83) 
119.95 
(100.50 – 
142.06) 
137.75 
(115.26 – 
163.36) 
Episodes (Groups 1-4) 91 120 93 77 
Incidence Rate (Groups 1-4) / 
100,000 person days (95% CI) 
65.95 
(53.10 – 
80.97) 
93.23 
(77.30-
111.48) 
83.25 
(67.19-
101.98) 
80.35 
(63.42-
100.43) 
Episodes (Groups 5-11) 86 54 41 55 
Incidence Rate (Groups 5-11) / 
100,000 person days (95% CI) 
62.32 
(49.85-
76.97) 
41.95 
(31.52-
54.74) 
36.70 
(26.34-
49.80) 
57.40 
(43.24-
74.71) 
Episodes (Groups 1 and 4 only) 78 81 74 43 
Incidence Rate (Groups 1 and 4 
only) / 100,000 person days (95% 
CI) 
56.5 
 
62.9 66.2 44.9 
 
Table 7. Cost-effectiveness estimates (95% CI) for the CHW intervention 
Additional total cost ($) per patient AUS $10,060 
Control event risk/population expected event risk for admission for 
diabetes acute complication and acute severe infection complication 
0.42 
Relative risk of hospital admission for diabetes acute complication 
and acute severe infection complication (Groups 1 and 4, 95% CI) 
0.59 (0.38 – 0.91) 
NNT 3 
Cost per hospital admission for diabetes acute complication and 
acute severe infection complication prevented  
AUS $30,180 
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Discussion 
We report here the results of two approaches to an economic evaluation of a pragmatic 
cluster RCT of a health-worker led care model for Aboriginal and TSI adults who have poorly 
controlled diabetes in remote Queensland communities. Both approaches use the same 
costing data but look at different outcomes. 
The first analysis looked at a range of clinical and QoL outcome measures, including the 
primary trial outcome of change in HbA1c as a measure of overall glycemic control, quality 
of life measures, modelling of disease progression, and hospitalisations overall. 
The second economic evaluation looked at the effect on those hospitalisations which would 
be expected to be impacted upon by the care model and which were shown to be reduced in 
a previous trial.26 
The conclusions from the first analysis show a disappointing result where the average per-
person cost at just over $6,700 per annum for the intensive IHW intervention (which is 
additional to regular primary care for medical, nursing, allied health services etc.), is high 
relative to reported costs of primary care in Indigenous communities in Australia. Gibson et 
al. estimated the mean primary care costs in 21 mainly remote Indigenous communities in 
north Queensland (including some of the same communities in this trial) at $1,825 in 2004-
05, equivalent to ~$2,700 in 2012/13.21 (This covered IHWs, medical, clinic health workers, 
nursing, managerial, clerical staff.) The AIHW reported total primary care expenditure per 
Indigenous person at a similar $2,648 in 2012/13.22   
A reduction in the number of participants with extremely poor control was also observed in 
the intervention sites, and it is these individuals who are at very high risk of renal disease 
and severe acute complications. The second economic analysis showed this effect, and the 
trial demonstrated a “number need to treat” (NNT) to prevent each such admission of only 
three, generally regarded as worth doing (if it was a drug trial for example). Participants in 
the intervention group were 40% less likely to be hospitalized for an acute infection or 
diabetic complication compared to the control group. The high cost of the intervention in this 
trial meant that each such admission prevented a cost of around $30,000. 
Workshops with service providers suggested that good community ‘buy-in’ was achieved 
through on-going community engagement with the IHW model building on the Apunipima 
Cape York Health Council (ACYHC) ‘family-centred’ approach, ACYHC as a partner in the 
trial and MW, Public Health Medical Advisor with ACYHC a CI on the project. 
Investment in the training, qualification upgrade and clinical support of the IHW is likely to 
generate value elsewhere in the health system and over the longer term, a likely benefit not 
captured in this evaluation. 
It is also worth reflecting on whether the presumed theory underpinning the trial was correct. 
In expanding the capacity of IHWs to provide direct and intensive support for indigenous 
patients in the community, through outreach as well as centre-based care, it was hoped to 
achieve more effective chronic disease management through greater cultural awareness 
and improved patient engagement in self-care mediated through a better trained and 
clinically supported IHW cohort. While some health gains were identified, given the high 
psychosocial and economic issues common in very disadvantaged populations, and the 
strong relationship between these factors and chronic disease, it may be necessary to 
address these factors more directly.23 Most of the IHW communities sit in the bottom 2% in 
terms of socio-economic disadvantage for Queensland, indicating an extreme level of 
deprivation, likely combined with a range of serious adversities.24 We did not have data on 
major life stressors (such as early death of family and friends, involvement with criminal 
justice or child protection systems) known to affect physical health and likely diabetes 
control; and these may occur differentially across the intervention and control communities. 
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Health services need to review their systems of care in order to maximise the value of IHWs 
as a specialist member of the multidisciplinary team. Case study material from the IHWs 
who participated in regular clinical review sessions identified examples of improved self-
management negotiated by the IHW25 consistent with better HbA1c results observed in 
patients with the poorest control, but also considerable patient disengagement. 
A more holistic cross-agency approach may be required, seeking to directly address the 
psychosocial, patho-physiological and environmental issues that are common in highly 
disadvantaged populations. While the need to address social and economic determinants is 
well understood, there are still major gaps in service delivery around these issues. And 
despite the widely observed co-occurrence of poor mental and physical health, which is 
most apparent in disadvantaged communities given high experiences of trauma, ensuring 
that psychological health receives priority attention within the primary care system is not 
necessarily occurring. The challenge is for the public health community to devise and 
implement interventions based on that broader understanding of the determinants of health 
and test their effectiveness. 
 
STUDY L IMITATIONS  
Limitations to our study include lower than expected patient recruitment, small numbers in 
two of the intervention sites, a relatively high loss to follow up (10%) which was higher in the 
intervention group and missing data for some of the secondary clinical endpoints. The latter 
was due to the pragmatic nature of the trial where clinical data was extracted from patient 
records. Other key developments which potentially limited the effectiveness of the study 
were major health system reform occurring in the Queensland government health services 
generally during the life of the trial, which limited the ability of the service to recruit and 
retain essential staff. These changes disproportionately affected four of the six intervention 
sites. Process evaluation found that all six health workers experienced higher workloads as 
the services expected them to undertake clinical work in addition to their study caseload. 
This tended to dilute the potential impact of their work on the care of study patients. 
The time window for the intervention (18 months) may have been too short to demonstrate a 
full effect, especially given the service interruptions happening at the time. A longer follow-
up period may have seen a greater effect in the communities where the HWs were operating 
at full capacity. 
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Conclusion 
Our results suggest that the costs of delivering the GBACC model were considerable in 
absolute terms and that the trial suffered from considerable implementation problems. The 
standard approach to the economic analysis (first evaluation) showed very modest impact 
for a relatively high cost intervention. The second analysis, which focused more on what the 
program would likely achieve in the short term (18 months) based on previous work 
published in this population (a reduction in acute sever hospitalisations due to infections and 
complications directly attributable to poor glycemic control) was more positive, with NNT of 
three. 
The training of IHWs and clinical support is generally viewed as positive, but translating that 
into measurable outcomes for persons with poorly controlled T2DM in highly disadvantaged 
communities represents a challenge.  
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